Sampre Nutritions Ltd has signed a significant 3-year manufacturing agreement worth ₹30 crore with Nigeria-based Tolaram Wellness Ltd, aimed at boosting its nutraceutical and food product portfolio.
Under this 3-year agreement, Sampre Nutritions will manufacture and supply nutraceutical and food products to Tolaram Wellness, generating ₹10 crore annually. The contract outlines quality standards, a 50% advance payment, and dispatch-based balance settlement. Transportation responsibilities lie with Tolaram Wellness. This agreement is not a related-party transaction, and Tolaram holds no equity in Sampre.
The move marks a clear step toward increasing Sampre’s global footprint while reinforcing its expertise in health-oriented food manufacturing.
Just days later, on August 19, 2025, Sampre signed another 3-year contract with Rama Exports for a projected ₹15 crore business. Sampre will handle manufacturing, packaging, and supply of products under Rama’s brand specifications. This further diversifies the company’s client base and strengthens its production scale.
For Q1FY26, ended June 30, 2025, Sampre reported ₹10.87 crore in revenue from operations, up 141% from ₹4.51 crore in Q1FY25. Net Profit surged 615% YoY to ₹70.76 lakh, compared to ₹9.89 lakh last year. Earnings Per Share rose to ₹0.34 from ₹0.11 in Q1FY25, reflecting improved profitability and operational efficiency.
On September 1, 2025, Sampre Nutritions share price opened at ₹80.09 on BSE. The stock is trading at ₹80.09 as of 10:29 AM. The stock hit an upper circuit of 2%.
Over the past week, it has moved up by 8.21%, over the past month, it has moved up by 48.35%, and over the past 3 months, it has moved up by 203.99%.
Sampre Nutritions’ ₹10 crore deal with Tolaram Wellness, along with recent partnerships and exceptional quarterly results, positions the company for sustained global growth. With strategic fundraising plans and industry recognition, Sampre is set to deepen its role in the nutraceutical and food manufacturing space.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Sep 1, 2025, 12:10 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
